Iconovo AB (SE:ICO)

:ICO

ICO

Iconovo AB

RESEARCH TOOLSreports

Want to see SE:ICO full AI Analyst Report?

Iconovo AB (ICO) Price & Analysis

1 Followers

ICO Stock Chart & Stats

kr1.12

-kr0.10(-3.02%)

At close: Mar 06 4:00 PM EST

kr1.12

-kr0.10(-3.02%)

Day’s Range― - ―

52-Week Rangekr0.91 - kr2.79

Previous CloseN/A

Volume7.53K

Average Volume (3M)46.24K

Market Cap

kr90.51M

Enterprise Valuekr24.72M

Total Cash (Recent Filing)kr49.25M

Total Debt (Recent Filing)kr5.70M

Price to Earnings (P/E)―

Beta-0.23

Next Earnings

Jul 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding74,800,380

10 Day Avg. Volume58,575

30 Day Avg. Volume46,237

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.37

Price to Sales (P/S)39.24

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)kr28.00M

Bulls Say, Bears Say

Bulls Say

Partnership- And Licensing-driven Business ModelThe partnership/licensing model is capital-light and scalable: milestones, royalties and development fees generate durable revenue streams when agreements close. This aligns with pharma outsourcing trends, allowing Iconovo to monetize IP without large manufacturing spend, supporting long-term cash generation when deals progress.

Supportive Balance Sheet With Very Low LeverageVery low debt and sizable equity versus assets provide a financial cushion against ongoing losses. Low leverage reduces refinancing and interest-cost risk, giving the company flexibility to fund R&D or bridge partner timelines without immediate solvency pressure, a durable advantage during development cycles.

Proprietary Inhaler Platforms And Device ExpertiseOwnership of inhaler platforms and device development capability creates IP barriers and makes Iconovo an attractive technology partner to pharma. Structural device know-how supports repeat licensing opportunities, long product lifecycles, and the potential for multiple, staggered revenue streams across inhaled therapy markets.

Bears Say

Negative Gross Profit And Heavy Operating LossesCore operations are currently loss-making with negative gross profit, indicating the business is not covering direct product and development costs. Persistent operating losses erode equity and limit the company’s ability to self-fund growth or absorb setbacks without material improvements in contracts or cost structure.

Consistent Negative Operating And Free Cash FlowMeaningful negative operating and free cash flow force reliance on external financing to fund operations and development. Even with a narrowed burn versus prior years, ongoing negative cash generation constrains long-term R&D spending and strategic optionality, increasing execution risk if funding access tightens.

Small, Volatile Revenue Base And Lumpy Top LineA small, lumpy revenue base driven by milestones and development contracts makes cash flows unpredictable. The modest TTM rebound reduces but doesn't eliminate revenue concentration risk; milestone timing and partner execution will continue to drive volatility and complicate multi-quarter planning.

ICO FAQ

What was Iconovo AB’s price range in the past 12 months?

Iconovo AB lowest stock price was kr0.91 and its highest was kr2.79 in the past 12 months.

What is Iconovo AB’s market cap?

Iconovo AB’s market cap is kr90.51M.

When is Iconovo AB’s upcoming earnings report date?

Iconovo AB’s upcoming earnings report date is Jul 10, 2026 which is in 66 days.

How were Iconovo AB’s earnings last quarter?

Iconovo AB released its earnings results on Apr 24, 2026. The company reported -kr0.105 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.105.

Is Iconovo AB overvalued?

According to Wall Street analysts Iconovo AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Iconovo AB pay dividends?

Iconovo AB does not currently pay dividends.

What is Iconovo AB’s EPS estimate?

Iconovo AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Iconovo AB have?

Iconovo AB has 74,800,380 shares outstanding.

What happened to Iconovo AB’s price movement after its last earnings report?

Iconovo AB reported an EPS of -kr0.105 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.478%.

Which hedge fund is a major shareholder of Iconovo AB?

Currently, no hedge funds are holding shares in SE:ICO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Iconovo AB

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.